3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
51
Lung Neoplasms
24
Parkinson Disease 4, Autosomal Dominant Lewy Body
22
Squamous Cell Carcinoma of Head and Neck
18
Neoplasm Metastasis
17
Melanoma
17
Neoplasms
16
Endometrial Neoplasms
14
Colorectal Neoplasms
14
Breast Neoplasms
14
Triple Negative Breast Neoplasms
12
Ovarian Neoplasms
11
Head and Neck Neoplasms
9
Pancreatic Neoplasms
7
Urinary Bladder Neoplasms
6
Carcinoma, Transitional Cell
6
Recurrence
5
Lymphoma
5
Hodgkin Disease
5
Carcinoma, Renal Cell
5
Esophageal Neoplasms
4
Carcinoma
4
Brain Neoplasms
4
Stomach Neoplasms
3
Small Cell Lung Carcinoma
3
Sarcoma
3
Fallopian Tube Neoplasms
3
Uterine Cervical Neoplasms
2
Urogenital Neoplasms
2
Ureteral Neoplasms
2
Interventions
pembrolizumab
1
Pemetrexed
1
Cisplatin
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplastic Processes
×
pembrolizumab
×
30 days
×
Clear all
NCT06119581
2026-06-03
SUNRAY-01
Eli Lilly and Company
Phase 3
Recruiting
1,264 enrolled